Trellus Management Company’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Trellus Management Company’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$2.26M	–	69
2022 Q3	$2.26M	Hold	10,000	–	–	2.74%	7
2022 Q2	$1.89M	Hold	10,000	–	–	2.3%	7
2022 Q1	$2.49M	Buy	10,000 +451	+5%	+$71.3K	1.45%	9
2021 Q4	$1.49M	Buy	9,549 +1,413	+17%	+$273K	0.99%	21
2021 Q3	$1.63M	Hold	8,136	–	–	1.19%	20
2021 Q2	$2.08M	Buy	8,136 +603	+8%	+$150K	1.44%	16
2021 Q1	$2M	Buy	7,533 +653	+9%	+$206K	1.04%	22
2020 Q4	$2.54M	Buy	6,880 +213	+3%	+$61.1K	2.09%	10
2020 Q3	$1.63M	Buy	6,667 +707	+12%	+$220K	1.67%	14
2020 Q2	$1.72M	Buy	5,960 +767	+15%	+$226K	1.86%	12
2020 Q1	$1.06M	Buy	5,193 +3,065	+144%	+$977K	1.9%	14
2019 Q4	$951K	Sell	2,128 -705	-25%	-$250K	1.59%	17
2019 Q3	$871K	Buy	2,833 +530	+23%	+$172K	0.87%	22
2019 Q2	$732K	Buy	+2,303	New	+$797K	0.99%	30

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Trellus Management Company's EIGR Position: Q4 2022 in Review

Trellus Management Company sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 10,000 shares — an estimated $2.26M sold.

Trellus Management Company first reported a position in EIGR in Q2 2019 and held it in 14 quarters. The position peaked at $2.54M in Q4 2020. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

Trellus Management Company reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Trellus Management Company sold 10,000 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $2.26M.
Trellus Management Company first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 14 quarters.
Trellus Management Company's Eiger BioPharmaceuticals, Inc. position peaked at $2.54M in Q4 2020.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Trellus Management Company's 13F filing for Q4 2022, filed 27 Jan 2023.